Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Q3 2025 earnings

Reported October 28, 2025 · Before market open

Revenue$99.2MMiss by $11.6M
EPS$0.06Beat by $0.16
Revenue estimate$110.8M
EPS estimate-$0.10

Next report

Oct 27, 2026 (in a month)
Revenue estimate$141.7M
EPS estimate$0.17

Financials

Q3 2025

Income statement

See full
Revenue$99.2M+122%
Gross profit$90.5M+131%
Operating income$8.5M+122%
Net income$7.4M+118%
EPS (diluted)$0.06+118%

Balance sheet

See full
Cash & equivalents$47.4M-65.0%
Total debt$113.8M-45.3%
Total equity$158.1M+0.9%
Total assets$371.0M-15.2%

Cash flow

See full
Operating cash flow-$1.8M+94.9%
Free cash flow-$1.8M+95.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.26B+108%
Enterprise value$2.33B+101%
P/S7.1×-0.7×

Profitability

See full
Gross margin90%+0.4pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.7×-0.6×
Current ratio3.5×+1.0×

Segments

By segment

See full
Reportable Segment$99.2M+122%

FAQ

When did Arcutis Biotherapeutics, Inc. report Q3 2025 earnings?
Arcutis Biotherapeutics, Inc. (ARQT) reported Q3 2025 earnings on October 28, 2025 before market open.
What were Arcutis Biotherapeutics, Inc.'s Q3 2025 revenue and EPS?
Arcutis Biotherapeutics, Inc. reported revenue of $99.2M and eps of $0.06 for Q3 2025.
Did Arcutis Biotherapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $110.8M by $11.6M. EPS beat the consensus estimate of $-0.10 by $0.16.
How did Arcutis Biotherapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 121.7% from $44.8M a year earlier.
Where can I find Arcutis Biotherapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001787306-25-000142) and the 10-Q periodic report (0001787306-25-000144) directly on SEC EDGAR. The filing index links above go to sec.gov.